This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: NeoStem, MannKind, Inovio



I find Neostem to be a very promotional company -- remember the Vatican stem-cell conference carnival? -- so let's just say be careful when CEO Robin Smith and her crew press release the AMR-001 data.

Speaking of Robin Smith and promotions, I wasn't joking when I predicted she'd restructure Neostem by launching a chain of stem-cell smoothie shops. In fact, Smith has already done it.

A few years ago, Smith partnered with a pyramid marketing company to concoct and sell a "liquid nutritional supplement" designed to "optimize" the health and function of adult stem cells.

This is my favorite YouTube video of Smith hawking her "AIO" stem cell beverage. I particularly like her white lab coat and the stethoscope slung across her neck. The snake oil sales pitch in the video really heats up at about 1:25.

Must Read: Everything You Need to Know About Biotech M&A in a Single Chart

It's hard to take Neostem and AMR-001 seriously while Smith runs the show.



Two emails, related, on MannKind (MNKD) and my prediction calling an FDA rejection of its inhaled, rapid-acting insulin Afrezza.

John T. writes:

Adam, long-time reader. What are the reasons you believe the FDA will reject MannKind's Afrezza? Just curious. Stock certainly sold off hard in August following MannKind's discussion of results. Is there something the company isn't telling us?

Jeff B says:

Adam, I strongly disagree with your negative article on MannKind Alfreeza. I don't think it will be rejected. Why do you and Cramer hate MannKind so much? I used to always respect and even manage my portfolio by what you guys said. But since I've owned MannKind I have been disappointed with both of yours comments. I have a MBA in Economics and respect most of what you say. I just don't see you two continuing to knock MannKind this third time around... I think you and Cramer will regret not being behind this one.

Here's my thinking on MannKind on why I predicted an FDA rejection of Afrezza:

The results from the two phase III studies announced this summer were barely passable. In Type 1 diabetics, Afrezza was numerically worse than Novo Nordisk's (NVO) Novolog. The study met its primary endpoint -- barely -- only because MannKind set a low bar with respect to the statistical non-inferiority endpoint.

Results from the study in Type 2 diabetics were more favorable for Afrezza but still, the product under-performed relative to MannKind's expectations. Afrezza also caused more weight gain in Type 2s.

We still don't know, exactly, how the current "Dreamboat" inhaler performed relative to the older Medtone inhaler. And MannKind has been flinty with Afrezza safety data. We know the inhaled insulin causes a persistent cough. MannKind claims the cough is benign, but what will FDA say?

Investors have not taken well to the Afrezza data. Here's a chart of MannKind plotted against the NBI since August. 



MNKD Chart
MNKD data by YCharts



2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARIA $7.79 0.13%
EXEL $5.54 -0.98%
INO $7.26 -1.90%
MNKD $4.46 0.45%
NBS $1.79 2.87%

Markets

Chart of I:DJI
DOW 17,733.53 -17.86 -0.10%
S&P 500 2,107.34 -1.23 -0.06%
NASDAQ 5,128.6250 +16.8920 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs